HUE065482T2 - Deuterált heterociklus-fúzionált gamma-karbolinok mint 5-HT2A receptorok antagonistái - Google Patents
Deuterált heterociklus-fúzionált gamma-karbolinok mint 5-HT2A receptorok antagonistáiInfo
- Publication number
- HUE065482T2 HUE065482T2 HUE15773589A HUE15773589A HUE065482T2 HU E065482 T2 HUE065482 T2 HU E065482T2 HU E15773589 A HUE15773589 A HU E15773589A HU E15773589 A HUE15773589 A HU E15773589A HU E065482 T2 HUE065482 T2 HU E065482T2
- Authority
- HU
- Hungary
- Prior art keywords
- carbolines
- antagonists
- heterocycle fused
- ht2a receptors
- fused gamma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461975610P | 2014-04-04 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE065482T2 true HUE065482T2 (hu) | 2024-05-28 |
Family
ID=54241342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15773589A HUE065482T2 (hu) | 2014-04-04 | 2015-04-03 | Deuterált heterociklus-fúzionált gamma-karbolinok mint 5-HT2A receptorok antagonistái |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10077267B2 (OSRAM) |
| EP (1) | EP3125893B1 (OSRAM) |
| JP (2) | JP2017509686A (OSRAM) |
| KR (2) | KR20170012210A (OSRAM) |
| CN (2) | CN111689966A (OSRAM) |
| AU (1) | AU2015240521B2 (OSRAM) |
| BR (1) | BR112016023162B1 (OSRAM) |
| CA (1) | CA2944512C (OSRAM) |
| DK (1) | DK3125893T3 (OSRAM) |
| ES (1) | ES2961843T3 (OSRAM) |
| HU (1) | HUE065482T2 (OSRAM) |
| IL (1) | IL248109B (OSRAM) |
| MX (3) | MX2021014508A (OSRAM) |
| PL (1) | PL3125893T3 (OSRAM) |
| PT (1) | PT3125893T (OSRAM) |
| RU (2) | RU2020123764A (OSRAM) |
| SI (1) | SI3125893T1 (OSRAM) |
| WO (1) | WO2015154025A1 (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| AU2009251816B2 (en) * | 2008-05-27 | 2015-12-10 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015085004A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20170012210A (ko) * | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| US20200392135A1 (en) * | 2016-03-25 | 2020-12-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| DK3407889T3 (da) * | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018106916A1 (en) * | 2016-12-07 | 2018-06-14 | Concert Pharmaceuticals, Inc. | Deuterated quinoxaline compounds |
| US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CN110087640A (zh) | 2016-12-20 | 2019-08-02 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| CN111093665A (zh) | 2017-07-26 | 2020-05-01 | 细胞内治疗公司 | 有机化合物 |
| JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| US10377708B2 (en) | 2017-12-05 | 2019-08-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| US11980617B2 (en) | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
| CN112088004A (zh) * | 2018-03-23 | 2020-12-15 | 细胞内治疗公司 | 有机化合物 |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2020013116A (es) * | 2018-06-06 | 2021-05-12 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7483671B2 (ja) * | 2018-06-11 | 2024-05-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ－カルボリン類合成 |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| BR112021001738A2 (pt) | 2018-06-21 | 2021-06-29 | Aquestive Therapeutics, Inc. | sistema e método para fabricação de doses unitárias individuais personalizadas contendo ativos farmacêuticos |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| JP7546546B2 (ja) | 2018-08-31 | 2024-09-06 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| AU2019331490B2 (en) | 2018-08-31 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN112955124A (zh) | 2018-09-07 | 2021-06-11 | 阿奎蒂夫疗法公司 | 具有精确的活性物溶出谱的口腔膜组合物和剂型 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CA3121631A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| JP7487204B2 (ja) | 2018-12-17 | 2024-05-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2020131911A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| JP7649743B2 (ja) | 2018-12-21 | 2025-03-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2020132474A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compound |
| JP2022535893A (ja) | 2019-06-04 | 2022-08-10 | サノビオン ファーマシューティカルズ インク | 放出調節製剤およびその使用 |
| EP4134101A1 (en) | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
| US12478623B2 (en) | 2019-09-25 | 2025-11-25 | Intra-Cellular Therapies, Inc. | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor |
| MX2022004983A (es) | 2019-11-01 | 2022-09-23 | Aquestive Therapeutics Inc | Composiciones de profarmaco y metodos de tratamiento. |
| CN115038451A (zh) | 2019-11-14 | 2022-09-09 | 阿奎斯蒂弗医疗股份有限公司 | 多模式组合物和治疗方法 |
| JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| EP4076461A4 (en) | 2019-12-19 | 2024-01-03 | Intra-Cellular Therapies, Inc. | Methods of schizophrenia treatment |
| MX2023004102A (es) * | 2020-10-09 | 2023-04-27 | Shujing Biopharma Co Ltd | Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. |
| US20220233471A1 (en) | 2021-01-15 | 2022-07-28 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| EP4304554A1 (en) | 2021-03-09 | 2024-01-17 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| AU2022328217A1 (en) | 2021-08-12 | 2024-03-14 | Kuleon Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| US20250145638A1 (en) * | 2021-12-22 | 2025-05-08 | Kuleon Llc | Serotonin Receptor Agonists and Methods of Making and Using the Same |
| TWI789217B (zh) * | 2022-01-21 | 2023-01-01 | 大陸商上海樞境生物科技有限公司 | 雜環取代的稠合γ-咔啉類衍生物、其製備方法、中間體及應用 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| AU2023272111A1 (en) | 2022-05-18 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN120282964A (zh) * | 2022-10-26 | 2025-07-08 | 上海枢境生物科技有限公司 | 一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用 |
| EP4642458A1 (en) | 2022-12-30 | 2025-11-05 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor |
| CN121152625A (zh) | 2023-02-17 | 2025-12-16 | 细胞内治疗公司 | 用于调节神经系统的卢美哌隆和其衍生物 |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS63501794A (ja) | 1985-10-09 | 1988-07-21 | デジテイン アルツナイミツテル ゲ−エムベ−ハ− | 医薬有効物質，試薬，その他の作用物質の提供ないし投与形態の製造法 |
| ZA871987B (en) | 1986-03-19 | 1988-05-25 | Kumiai Chemical Industry Co | 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same |
| ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| DE4018247A1 (de) | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| HU219487B (hu) | 1993-11-19 | 2001-04-28 | Janssen Pharmaceutica Nv. | Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk |
| US5763476A (en) | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CA2186371A1 (en) * | 1994-03-25 | 1995-10-05 | Robert T. Foster | Enhancement of the efficacy of dihydropyridines by deuteration |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| US6395939B1 (en) | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| JP4647780B2 (ja) | 1998-02-26 | 2011-03-09 | マサチューセッツ インスティテュート オブ テクノロジー | ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化 |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| DE69935933T2 (de) | 1998-07-10 | 2008-01-10 | Massachusetts Institute Of Technology, Cambridge | Liganden für Metalle und verbesserte Metall-katalysierte Verfahren, die darauf basieren |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| CN1161101C (zh) | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统 |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| NO309305B1 (no) | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
| AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| HK1043112A1 (zh) | 1999-06-15 | 2002-09-06 | Bristol-Myers Squibb Pharma Company | 取代的稠杂环γ-咔啉 |
| PT1104760E (pt) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| HUP0303432A3 (en) | 2000-12-20 | 2012-09-28 | Bristol Myers Squibb Co | Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use |
| EP1390340B1 (en) | 2001-04-24 | 2017-03-01 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| DE10123129A1 (de) | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| WO2003014118A1 (en) | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
| DE10162121A1 (de) | 2001-12-12 | 2003-06-18 | Berolina Drug Dev Ab Svedala | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
| JP4500679B2 (ja) | 2002-07-29 | 2010-07-14 | アルザ・コーポレーシヨン | パリペリドンを制御送達する方法および投薬形態物 |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US6888032B2 (en) | 2002-08-02 | 2005-05-03 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| US20040142970A1 (en) | 2002-11-01 | 2004-07-22 | Kathryn Chung | Treatment of hyperkinetic movement disorder with donepezil |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| ES2364046T3 (es) | 2002-12-19 | 2011-08-23 | Bristol-Myers Squibb Company | Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina. |
| CN1852893A (zh) | 2003-07-21 | 2006-10-25 | 史密丝克莱恩比彻姆公司 | (2S,4S)－4－氟－1－[4－氟－β－(4－氟苯基)－L－苯基丙氨酰基]－2－吡咯烷甲腈对甲苯磺酸盐及其无水晶体形式 |
| TW200514785A (en) * | 2003-09-26 | 2005-05-01 | Solvay Pharm Bv | Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| EP1756102A1 (en) | 2004-03-05 | 2007-02-28 | Pharma C S.A. | 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| WO2006034187A2 (en) | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| WO2006032999A1 (en) | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
| US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
| MX2007006896A (es) | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| KR20070099031A (ko) | 2005-01-25 | 2007-10-08 | 셀진 코포레이션 | 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물 |
| US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| JP2009523734A (ja) | 2006-01-13 | 2009-06-25 | ワイス | ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| WO2009017836A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| NO2180844T3 (OSRAM) | 2007-08-02 | 2018-07-21 | ||
| EP2190844B3 (en) * | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| US20090209608A1 (en) | 2007-08-29 | 2009-08-20 | Protia, Llc | Deuterium-enriched asenapine |
| US20090076159A1 (en) | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched eplivanserin |
| EP2262502A4 (en) | 2008-02-05 | 2011-12-28 | Clera Inc | Compositions and methods for alleviating depression or improving cognition |
| MX2010010024A (es) | 2008-03-12 | 2010-11-09 | Intra Cellular Therapies Inc | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
| AU2009251816B2 (en) | 2008-05-27 | 2015-12-10 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
| US20100159033A1 (en) | 2008-09-29 | 2010-06-24 | Auspex Pharmaceuticals, Inc. | Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor |
| US8778893B2 (en) * | 2009-10-05 | 2014-07-15 | Bristol-Myers Squibb Company | (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites |
| CN103209704B (zh) | 2010-04-22 | 2017-10-27 | 细胞内治疗公司 | 有机化合物 |
| ES2791715T3 (es) | 2010-12-16 | 2020-11-05 | Sunovion Pharmaceuticals Inc | Películas sublinguales |
| US8697700B2 (en) * | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
| AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR092568A1 (es) | 2012-09-14 | 2015-04-22 | Abbvie Deutschland | Derivados triciclicos de quinolinas y de quinoxalinas |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| DK3043777T3 (da) | 2013-09-10 | 2020-07-20 | Fresh Cut Dev Llc | Sublingual buprenorphinspray |
| WO2015085004A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20170012210A (ko) * | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| EP4512394A3 (en) | 2015-06-03 | 2025-10-22 | Triastek, Inc. | Dosage forms and use thereof |
| WO2017117514A1 (en) | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| DK3407889T3 (da) * | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| US20200392135A1 (en) | 2016-03-25 | 2020-12-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018106916A1 (en) | 2016-12-07 | 2018-06-14 | Concert Pharmaceuticals, Inc. | Deuterated quinoxaline compounds |
| WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
-
2015
- 2015-04-03 KR KR1020167030588A patent/KR20170012210A/ko not_active Ceased
- 2015-04-03 MX MX2021014508A patent/MX2021014508A/es unknown
- 2015-04-03 KR KR1020227013900A patent/KR20220054908A/ko not_active Ceased
- 2015-04-03 JP JP2016560817A patent/JP2017509686A/ja active Pending
- 2015-04-03 PL PL15773589.5T patent/PL3125893T3/pl unknown
- 2015-04-03 CN CN202010673415.0A patent/CN111689966A/zh active Pending
- 2015-04-03 US US15/301,912 patent/US10077267B2/en active Active
- 2015-04-03 WO PCT/US2015/024340 patent/WO2015154025A1/en not_active Ceased
- 2015-04-03 MX MX2019007474A patent/MX388258B/es unknown
- 2015-04-03 RU RU2020123764A patent/RU2020123764A/ru unknown
- 2015-04-03 EP EP15773589.5A patent/EP3125893B1/en active Active
- 2015-04-03 AU AU2015240521A patent/AU2015240521B2/en active Active
- 2015-04-03 MX MX2016013050A patent/MX365969B/es active IP Right Grant
- 2015-04-03 SI SI201531974T patent/SI3125893T1/sl unknown
- 2015-04-03 CN CN201580028561.5A patent/CN106535898A/zh active Pending
- 2015-04-03 PT PT157735895T patent/PT3125893T/pt unknown
- 2015-04-03 BR BR112016023162-7A patent/BR112016023162B1/pt active IP Right Grant
- 2015-04-03 HU HUE15773589A patent/HUE065482T2/hu unknown
- 2015-04-03 CA CA2944512A patent/CA2944512C/en active Active
- 2015-04-03 ES ES15773589T patent/ES2961843T3/es active Active
- 2015-04-03 DK DK15773589.5T patent/DK3125893T3/da active
- 2015-04-03 RU RU2016143357A patent/RU2728787C2/ru active
-
2016
- 2016-09-28 IL IL24810916A patent/IL248109B/en active IP Right Grant
-
2018
- 2018-08-03 US US16/054,728 patent/US10597394B2/en active Active
-
2019
- 2019-10-10 JP JP2019186516A patent/JP2020079231A/ja active Pending
-
2020
- 2020-02-10 US US16/786,240 patent/US10899762B2/en active Active
- 2020-12-16 US US17/124,224 patent/US11560382B2/en active Active
-
2022
- 2022-12-16 US US18/067,387 patent/US12269825B2/en active Active
-
2025
- 2025-02-28 US US19/066,829 patent/US20250243201A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3125893T3 (pl) | Deuterowane gamma-karboliny w fuzji z heterocyklami jako antagoniści receptorów 5-HT2A | |
| ZA202007276B (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
| PL3233863T3 (pl) | Związki heteroarylowe ze skondensowanymi pierścieniami i ich zastosowanie jako inhibitorów trk | |
| IL246140B (en) | History of bicyclic heterocyclics as bromodomain repressors | |
| PL3099720T3 (pl) | Zastosowanie dodatków opartych na kwasach polikarboksylowych do paliw silnikowych | |
| IL246838A0 (en) | A fused heterocyclic compound | |
| DK3143037T3 (da) | Alpha4beta7-integrin-thioether-peptidantagonister | |
| DK3212637T3 (da) | Dopamin-d3-receptorantagonistforbindelser | |
| IL247143B (en) | A new use of agonistic compounds for the sigma-1 receptor | |
| IL250613B (en) | Substituted bicyclic compounds | |
| ZA201704462B (en) | New benzimidazole derivatives as antihistamine agents | |
| GB201416052D0 (en) | Configuration of user Interface | |
| IL251559B (en) | Pharmaceutical preparations of the history of aminodihydrothiazines from Amano | |
| TH1501007504A (th) | การใช้เซอร์โลพิแทนต์ซึ่งเป็นnk-1 รีเซพเตอร์แอนทาโกนิสต์ ในอาการคัน | |
| TWM489488U (en) | Improved structure of foot ring | |
| TH1601003290A (th) | สารประกอบไบไซคลิกเฮเทอโรไซเคิล | |
| GB201419433D0 (en) | Dopamine D3 receptor antagonist compounds | |
| GB201419430D0 (en) | Dopamine D3 receptor antagonist compounds | |
| TH1501006213A (th) | รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์ |